142 citations
,
March 2019 in “Molecules/Molecules online/Molecules annual” This review discusses the role of the endocannabinoid system in skin health and disease, highlighting its potential for future research and applications, but reports no new experimental results.
66 citations
,
February 2013 in “PeerJ” This study found that CB1 activation by a specific agonist led to decreased expression of keratins K6 and K16 in human skin and inhibited keratinocyte proliferation, suggesting potential for cannabinoid receptors in psoriasis management.
50 citations
,
May 2019 in “Drugs” This review discusses the potential therapeutic effects of targeting the endocannabinoid system for chemotherapy-induced peripheral neuropathy and reports no new clinical results, highlighting the need for ongoing research.
20 citations
,
August 2021 in “Journal of Cosmetic Dermatology” This review examines the potential use and challenges of topical cannabinoids for skin diseases and hair growth, highlighting limited clinical data on their efficacy and safety.
14 citations
,
February 2021 in “Experimental Dermatology” This study found that activating CB1 receptor signaling in human hair follicles increased stem cell proliferation while reducing differentiated cell survival, suggesting CB1's role as a survival stimulus for epithelial stem cells.
13 citations
,
May 2021 in “FASEB bioAdvances” This review discusses plant-based alternatives to retinoids for dermal antiaging and hair health, highlighting roles for cytokinins and phytoestrogens and reports no new results.
6 citations
,
June 2023 in “American Society of Clinical Oncology Educational Book” This review highlights emerging strategies to manage chemotherapy side effects like nausea, neuropathy, and alopecia, noting that scalp cooling has been effective for reducing hair loss, while cryotherapy and cannabis show promise but need further study for side effect management.
3 citations
,
December 2022 in “Cells” This review examines the role of cannabinoid compounds in treating various skin conditions and suggests their potential as systemic and topical therapies, but it reports no new experimental results.
3 citations
,
January 2023 in “Clinical cancer investigation journal” This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.
2 citations
,
September 2023 in “Cosmetics” This study reviewed existing research on the use of cannabinoids for hair, scalp, and skin conditions, finding moderate evidence for their efficacy in conditions like atopic dermatitis and psoriasis, but noted limited evidence and no standardized guidelines for treatment.
2 citations
,
October 2022 in “Journal of cosmetic dermatology” This study observed that a CBD-rich topical cannabis extract may increase hair count in patients with androgenetic alopecia when applied daily, but the effect is concentration-dependent and requires further research to establish safety and efficacy.
1 citations
,
November 2025 in “Journal of Education Health and Sport” This study suggests that cannabinoids, especially CBD, show promise as potential treatments for various inflammatory, infectious, and autoimmune skin diseases, with ongoing research needed to confirm clinical efficacy and safety.
1 citations
,
February 2024 in “Cosmetics” In this review, researchers explored the potential of cannabinoids, particularly cannabidiol, as a holistic treatment for acne vulgaris, highlighting their lipostatic, anti-inflammatory, antiproliferative, and antimicrobial effects in modulating acne-related factors like sebum production and inflammation.
1 citations
,
November 2023 in “International journal of molecular sciences” This article highlights that while cannabinoids show potential for treating various skin conditions, current evidence is largely preclinical, with a need for comprehensive clinical trials to confirm these promising effects.
March 2025 in “Journal of Investigative Dermatology” In this survey study, 44% of epidermolysis bullosa patients who tried cannabinoids reported effective symptom management, particularly pain relief, but concerns about cost, stigma, and accessibility remain significant. Further research is necessary to confirm these findings and optimize cannabinoid therapies for EB.
May 2024 in “International Journal of Nanomedicine” This review examined the diverse therapeutic potentials of cannabinoids, highlighting their applications in pain, neurological, and cancer treatments, and emphasized the benefits of biodegradable polymers in improving drug delivery; however, further clinical trials are needed to fully explore these potentials.
January 2024 in “Clinical dermatology open access journal” This paper reviews existing research on the cosmetic benefits of hemp-derived cannabinoids for skin and hair, highlighting their unique mechanisms of action, while discussing formulation, legal, and regulatory challenges associated with using these compounds in cosmetic products.
January 2022 in “Clinical dermatology open access journal” This review summarizes research on cannabinoids like CBD and THCV, reporting that they improve hair growth in patients with androgenetic alopecia when applied topically, with CBD showing a dose-dependent effect.
April 2012 in “J. Willard Marriott Library” This study concluded that THC and THCA incorporate into hair by a mechanism independent of hair pigmentation, likely influenced by indirect deposition via sebum and skin.
This study found that activating cannabinoid receptor 1 reduces the expression of keratins K6 and K16 in human keratinocytes, suggesting potential implications for psoriasis management.
This study found that CB1 receptor activation reduced keratin K6 and K16 expression in human keratinocytes in vitro and in situ, suggesting potential relevance for both psoriasis management and wound healing.
January 2022 in “International review of movement disorders” In this review, the authors found that cannabinoids and steroid-related drugs show potential for treating Tourette syndrome, but existing evidence is limited and further research is needed to confirm their efficacy and safety.
28 citations
,
January 2017 in “EBioMedicine” This study discusses potential anti-inflammatory roles of endocannabinoid system modulation and phytocannabinoids in skin health, but reports no new clinical results; the authors emphasize the need for further clinical exploration.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” This study observed that in an ex vivo setting, 17β-estradiol increased CB1 expression in human hair follicles, suggesting possible sensitivity to endocannabinoids and a potential mechanism for hair therapy.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports that cannabinoid receptor type 1 may influence psoriasis development by modulating laminin-511 expression, suggesting a potential target for treatment.
14 citations
,
March 2016 in “Cutaneous and Ocular Toxicology” This study observed that SC users commonly exhibited dermatological findings like periorbital darkening and blade scars, highlighting the importance for dermatologists to recognize these markers for early diagnosis and intervention.
22 citations
,
February 2002 in “European Neuropsychopharmacology” The researchers found that using hair analysis to detect past use of cannabinoids or amphetamines in individuals with psychosis was limited by individual variations in hair growth rates, affecting the method's reliability.
157 citations
,
April 1997 in “International journal of legal medicine” This study found that cosmetic hair treatments like bleaching and dyeing significantly reduced drug concentrations in hair samples, with decreases ranging from 30% to over 60% depending on the treatment and hair damage level.
124 citations
,
January 2012 in “Journal of Allergy and Clinical Immunology” This study found that activation of cannabinoid 1 receptors in human scalp hair follicles may limit excessive mast cell activation and maturation, suggesting a potential therapeutic strategy for managing MC-dependent skin diseases.
75 citations
,
August 2018 in “Biochemical pharmacology” This review discusses the potential of targeting the endocannabinoid system for treating skin disorders and reports no new clinical results, highlighting the need for further research.